Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04615572 · ClinicalTrials.gov registry record
Screening to Improve Survival in AL Amyloidosis
A clinical trial, sponsored by Tufts Medical Center.
- Completed
- Registry status
- 35
- Enrollment target
NCT04615572 is a clinical trial that has completed, run by Tufts Medical Center. The registered enrollment target is 35 participants.
The verdict
NCT04615572 has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2023-07-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04615572
The ClinicalTrials.gov registry entry for NCT04615572 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04615572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04615572 about?
NCT04615572 is a clinical study titled "Screening to Improve Survival in AL Amyloidosis". The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The c...
What is the current status of trial NCT04615572?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2020-08-28. Estimated completion is 2023-07-06.
Who is sponsoring clinical trial NCT04615572?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.